<DOC>
	<DOC>NCT01137838</DOC>
	<brief_summary>To compare the proportion of rheumatoid arthritis (RA) patients prescribed opioids, benzodiazepines, and antidepressants before versus after starting each of the following biologics: abatacept, infliximab, etanercept, adalimumab, utilizing an administrative claims database.</brief_summary>
	<brief_title>Changes in the Use of Opioids, Antidepressants, and Benzodiazepines in Rheumatoid Arthritis Patients Treated With Biologic Agents</brief_title>
	<detailed_description />
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis, Rheumatoid</mesh_term>
	<mesh_term>Antidepressive Agents</mesh_term>
	<criteria>ICD 9 diagnosis RA 714.0 Documented first biologic prescription ("index" prescription) for abatacept, infliximab, etanercept, or adalimumab Continuous therapy (gap between scripts no greater than 150% days supply) for minimum 6 months from index Prescription claims data available for 6 months before and 12 months after index biologic prescription Continuous eligibility for 6 months before and 12 months after index biologic prescription Prescription claims for another biologic during the observation period (including rituximab and anakinra) Prescriptions not continuous for at least 6 months</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2011</verification_date>
</DOC>